39 studies found for:    Open Studies | "beta-Thalassemia"
Show Display Options
Rank Status Study
21 Recruiting Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease and Beta-Thalassemia
Conditions: Peripheral Blood Stem Cell Transplantation;   Anemia, Sickle Cell;   Graft-Versus-Host Disease;   Sirolimus (Rapamune );   Alemtuzumab (Campath )
Interventions: Procedure: PBMC Transplant;   Drug: Alemtuzumab (Campath );   Drug: Sirolimus (Rapamune );   Drug: Cyclophosphamide (Cytoxan );   Procedure: Low Dose Irradiation
22 Not yet recruiting The Effect of Vitamin D Supplementation on Calcium Excretion in Thalassemia: a Dose Response Study
Condition: Thalassemia Major
Interventions: Drug: Vitamin D3;   Drug: Placebo
23 Not yet recruiting Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia.
Condition: Thalassemia Major
Intervention: Drug: INC424 (ruxolitinib)
24 Recruiting High-Tc Susceptometer to Monitor Transfusional Iron Overload
Conditions: Transfusional Iron Overload;   Thalassemia Major;   Sickle Cell Disease;   Myelodysplastic Syndromes;   Aplastic Anemia
Intervention: Device: Hepatic biomagnetic susceptibility measurement
25 Recruiting Combination Deferasirox and Deferiprone for Severe Iron Overload in Thalassemia
Condition: Thalassemia Major With Severe Transfusional Iron Overload
Intervention: Drug: Deferasirox and deferiprone
26 Recruiting Endocrine and Nutritional Assessment in B Thalassemia Major
Condition: Thalassemia
Intervention: Other: Nutritional recommendations
27 Unknown  GDF 15 in Sickle Cell Disease and Hereditary Spherocytosis
Conditions: Patients With Thalassemia Intermedia,;   Congenital Dyserythropoietic Anemia Type I
Intervention:
28 Unknown  Amlodipine in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major
Conditions: Thalassemia;   Iron Overload
Intervention: Drug: Amlodipine
29 Recruiting Demographic, Clinical, Laboratory and Genetical Characteristics of Patients With Beta Thalassemia Intermedia
Condition: Thalassemia
Intervention: Genetic: Laboratory analysis.
30 Recruiting Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure
Conditions: Sickle Cell Disease;   Thalassemia;   Stem Cell Transplantation;   Graft vs Host Disease
Interventions: Drug: Alemtuzumab;   Drug: Sirolimus;   Drug: Cyclophosphamide;   Drug: Pentostatin;   Drug: Radiotherapy
31 Unknown  Interferon and Ribavirin Treatment in Patients With Hemoglobinopathies
Condition: Hemoglobinopathies
Intervention: Drug: PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin
32 Recruiting Iron Overload and Growth Velocity in Thalassemia and Sickle Cell Anemia
Conditions: Thalassemia;   Sickle Cell Disease
Intervention: Other: Medical Chart Summary
33 Recruiting CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant
Conditions: Chronic Myeloid Leukemia (CML);   Acute Myelogenous Leukemia (AML);;   Myelodysplastic Syndrome (MDS);;   Juvenile Myelomonocytic Leukemia (JMML);;   Acute Lymphoblastic Leukemia (ALL);;   Lymphoma (Hodgkin's and Non-Hodgkin's)
Interventions: Device: CliniMACS CD34+ Reagent System;   Drug: Thiotepa;   Drug: Cyclophosphamide;   Drug: Alemtuzumab;   Drug: Tacrolimus;   Drug: Melphalan;   Drug: Busulfan;   Drug: Fludarabine
34 Recruiting Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
Condition: Sickle Cell Disease
Intervention: Drug: panobinostat
35 Not yet recruiting Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric Patients
Condition: Chronic Iron Overload
Interventions: Drug: Deferiprone;   Drug: Deferasirox
36 Recruiting Pharmacokinetic Study of Deferiprone in Paediatric Patients
Condition: Chronic Iron Overload
Intervention: Drug: Deferiprone
37 Recruiting Utility of Fibroscan in Estimating Hepatic Iron Concentration
Condition: Hereditary Anemias
Intervention: Procedure: Fibroscan
38 Unknown  Phase II Randomized Trial of Arginine Butyrate Plus Standard Local Therapy in Patients With Refractory Sickle Cell Ulcers
Conditions: Skin Ulcers;   Sickle Cell Anemia
Intervention: Drug: arginine butyrate
39 Recruiting Reduced Intensity Conditioning in Patients Aged ≤30 With Non-Malignant Disorders Undergoing Cord Blood Transplantation
Conditions: Primary Immunodeficiency Syndromes;   Congenital Bone Marrow Failure Syndromes;   Inherited Metabolic Disorders (IMD);   Hereditary Anemias;   Patients With Sickle Disease Presenting Specific Symptoms
Interventions: Drug: Hydroxyurea;   Drug: Alemtuzumab;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Thiotepa

Show previous page of results Previous Page (1-20) Studies Shown (21-39) Next Page
Indicates status has not been verified in more than two years